药品市场规模、份额、增长分析、按分子、副产品、按类型、按疾病、按给药方法、按处方、按年龄、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球药品市场规模为2098.5亿美元，从2023年的2224.4亿美元增长到2031年的3545.4亿美元，预计在预测期内（2024-2031年）将以6.0%的复合年增长率增长。

药品被定义为用于医疗目的的含有药物的产品，由于消费者健康意识的增强，需求正在迅速增长。这种趋势在 COVID-19 大流行期间加速，负责疫苗开发的製药公司不仅生存下来，而且在经济不确定的情况下蓬勃发展，凸显了该行业的弹性。随着人们优先考虑自己的健康，药品市场可望持续成长。我们对医疗保健解决方案的持续承诺强调了药物在社会中的重要作用，并确保只要公共卫生需求持续存在，市场就会持续扩张。透过专注于创新和可及性，製药业有望满足未来消费者不断变化的需求。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

药品市场规模：依分子及复合年增长率（2024-2031）

• 市场概况
• 生技药品和生物相似药（大分子）
• 常规药物（小分子）

医药市场规模：依产品及复合年增长率（2024-2031）

• 市场概况
• 品牌
• 非专利的

药品市场规模：按类型及复合年增长率（2024-2031）

• 市场概况
• 处方笺
• 在商店

药品市场规模：依疾病及复合年增长率（2024-2031）

• 市场概况
• 心血管疾病
• 癌症
• 糖尿病
• 感染疾病
• 神经系统疾病
• 呼吸系统疾病
• 自体免疫疾病
• 精神疾病
• 胃肠道疾病
• 女性健康疾病
• 遗传和罕见遗传疾病
• 皮肤病
• 肥胖
• 肾臟疾病
• 肝臟疾病
• 血液疾病
• 眼睛状况
• 不孕症
• 内分泌疾病
• 过敏
• 其他的

药品市场规模：依给药方式及复方年增长率（2024-2031）

• 市场概况
• 口服
• 局部的
• 胃肠外的
  • 静脉
  • 肌肉注射
• 吸入
• 其他的

药品市场规模：依处方及复合年增长率（2024-2031）

• 市场概况
• 药片
• 胶囊
• 注射
• 喷
• 暂停
• 粉末
• 其他处方

医药市场规模：依年龄及复合年增长率（2024-2031）

• 市场概况
• 儿童和青少年
• 成人
• 老年病

药品市场规模：依最终用途及复合年增长率（2024-2031）

• 市场概况
• 医院
• 诊所
• 其他的

医药市场规模及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Pfizer（USA）
• Johnson & Johnson（USA）
• Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co.（USA）
• AbbVie（USA）
• Bristol Myers Squibb（USA）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• Sanofi（France）
• AstraZeneca（UK）
• Amgen（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck KGaA（Germany）
• Vertex Pharmaceuticals Incorporated（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Alexion Pharmaceuticals, Inc.（USA）
• Astellas Pharma Inc.（Japan）

结论和建议

Global Pharmaceuticals Market size was valued at USD 209.85 billion in 2022 and is poised to grow from USD 222.44 billion in 2023 to USD 354.54 billion by 2031, growing at a CAGR of 6.0% during the forecast period (2024-2031).

Pharmaceuticals, defined as drug-containing products formulated for medical purposes, are witnessing a surge in demand, driven by increasing consumer awareness about health and wellness. This trend accelerated during the COVID-19 pandemic, where pharmaceutical companies responsible for vaccine development not only survived but thrived amidst economic instability, highlighting the sector's resilience. As individuals prioritize their health, the pharmaceutical market is poised for continued growth. The ongoing commitment to healthcare solutions underscores the essential role of pharmaceuticals in society, ensuring sustained market expansion as long as public health needs persist. With a focus on innovation and accessibility, the industry is well-positioned to meet the evolving demands of consumers in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceuticals Market Segmental Analysis

Global Pharmaceuticals Market is segmented by molecule, product, type, disease, administration, formulation, age, end use and region. Based on molecule, the market is segmented into biologics & biosimilars (large molecules) and conventional drugs (small molecules). Based on product, the market is segmented into branded and generic. Based on type, the market is segmented into prescription and OTC. Based on disease, the market is segmented into cardiovascular diseases, cancer, diabetes, infectious diseases, neurological disorders, respiratory diseases, autoimmune diseases, mental health disorders, gastrointestinal disorders, women's health diseases, genetic and rare genetic diseases, dermatological conditions, obesity, renal diseases, liver conditions, hematological disorders, eye conditions, infertility conditions, endocrine disorders, allergies and others. Based on administration, the market is segmented into oral, topical, parenteral, inhalations and other. Based on formulation, the market is segmented into tablets, capsules, injectable, sprays, suspensions, powders and other formulations. Based on age, the market is segmented into children & adolescents, adults and geriatric. Based on end use, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceuticals Market

One of the key drivers of the Global Pharmaceuticals market is the rising aging population. Recent data from the Bureau of Census highlights a growth in the demographic of individuals aged 65 and older, increasing from 8% in 2015 to 9% in 2021. This demographic shift results from improved living standards and an expanding global population, significantly altering the population structure in many nations. The United Nations projects a staggering 56% rise in individuals aged 60 and above from 2015 to 2030. As people live longer, age-related health issues are becoming more prevalent, putting enormous pressure on healthcare systems worldwide. This scenario creates a critical need for innovative pharmaceutical solutions, as advancements in nanotechnology and artificial intelligence offer promising avenues to develop new treatments. Consequently, the growing patient base directly fuels the demand for medical interventions, driving substantial growth in the pharmaceuticals market.

Restraints in the Global Pharmaceuticals Market

The global pharmaceuticals market faces significant restraints stemming from a shortage of skilled labor and the volatility of raw material costs. The development of new drugs necessitates specialized skill sets that are currently available only in select research organizations, leading to an inadequate workforce. Additionally, fluctuating raw material prices hinder market expansion, creating further challenges for pharmaceutical companies. Compounding these issues is a pronounced talent gap, as the skills possessed by the current workforce do not adequately align with the advanced requirements of biopharma production. Companies struggle to find expertise in critical areas like automation, computer science, and process modeling, hindering innovation and progress within the industry.

Market Trends of the Global Pharmaceuticals Market

The Global Pharmaceuticals market is experiencing a significant trend toward restructuring and recovery post-COVID-19, as companies adapt to the new normal. As the demand for innovative therapies surges, firms are pivoting their business models to enhance resilience against future disruptions. The pandemic catalyzed a shift to digital health solutions and telemedicine, prompting pharmaceutical companies to invest in technology and streamline operations. There is also an increased focus on supply chain diversification and sustainability practices. This evolving landscape presents opportunities for growth and collaboration, positioning the pharmaceutical sector for a robust rebound and long-term evolution in healthcare delivery and access.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pharmaceuticals Market Size by Molecule & CAGR (2024-2031)

• Market Overview
• Biologics & Biosimilars (Large Molecules)
• Conventional Drugs (Small Molecules)

Global Pharmaceuticals Market Size by Product & CAGR (2024-2031)

• Market Overview
• Branded
• Generic

Global Pharmaceuticals Market Size by Type & CAGR (2024-2031)

• Market Overview
• Prescription
• OTC

Global Pharmaceuticals Market Size by Disease & CAGR (2024-2031)

• Market Overview
• Cardiovascular Diseases
• Cancer
• Diabetes
• Infectious Diseases
• Neurological Disorders
• Respiratory Diseases
• Autoimmune Diseases
• Mental Health Disorders
• Gastrointestinal Disorders
• Women'S Health Diseases
• Genetic and Rare Genetic Diseases
• Dermatological Conditions
• Obesity
• Renal Diseases
• Liver Conditions
• Hematological Disorders
• Eye Conditions
• Infertility Conditions
• Endocrine Disorders
• Allergies
• Others

Global Pharmaceuticals Market Size by Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Topical
• Parenteral
  • Intravenous
  • Intramuscular
• Inhalations
• Other

Global Pharmaceuticals Market Size by Formulation & CAGR (2024-2031)

• Market Overview
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations

Global Pharmaceuticals Market Size by Age & CAGR (2024-2031)

• Market Overview
• Children & Adolescents
• Adults
• Geriatric

Global Pharmaceuticals Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Others

Global Pharmaceuticals Market Size & CAGR (2024-2031)

• North America (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • USA
  • Canada
• Europe (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations